The Benign Prostatic Hyperplasia (BPH) Treatment Market was valued at USD 1.57 billion in 2023 and is projected to reach USD 3.38 billion by 2032, growing at a CAGR of 8.92% over the forecast period 2024-2032. The increasing global burden of BPH, coupled with technological advancements in treatment modalities and the rising adoption of minimally invasive...